



# Investigation of Fungal Colonization Among Iranian Patients with Idiopathic Pulmonary Fibrosis; Molecular Identification and Antifungal Susceptibility Pattern

Maryam Roudbary<sup>1,\*</sup>, Hossein Keyvani<sup>2</sup>, Seyed Ali Javad Mousavi<sup>3</sup>, Maryam Esghaei<sup>2</sup>, Shahla Roudbarmohammadi<sup>4</sup>, Neda Hedayati<sup>5</sup>, Ghazaleh Salehabadi<sup>5</sup>, Mehraban Falahati<sup>1</sup> and Mahtab Ashrafi khozani<sup>1</sup>

<sup>1</sup>Department of Medical Mycology and Parasitology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

<sup>2</sup>Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

<sup>3</sup>Department of Internal Medicine, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

<sup>4</sup>Department of Mycology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

<sup>5</sup>Student Research Committee, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

\*Corresponding author: Department of Medical Mycology and Parasitology, School of Medicine, Iran University of Medical Sciences, Postal Code: 14496-14530, Tehran, Iran. Email: roudbari.mr@iums.ac.ir; m\_roudbary@yahoo.com

Received 2017 December 31; Revised 2018 August 01; Accepted 2018 November 05.

## Abstract

**Background:** Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease. In patients with lung tissue damage, fungal colonization leads to persistent infection. It is expected for there to be an association between fungal agents and etiology of IPF.

**Objectives:** The aim of this study was to investigate the prevalence and molecular identification of fungal species isolated from IPF patients for the first time in Iran. Also, in vitro anti-fungal susceptibility testing of isolates was demonstrated.

**Methods:** Forty nasopharyngeal (NP) swabs or bronchoalveolar lavage (BAL) samples were obtained from Iranian patients with IPF, who were diagnosed by a sophisticated practitioner from year 2015 to 2016 (Tehran, Iran). Direct examination of samples was carried out using hydroxide potassium (KOH) for detection of fungal elements. The specimens were cultured on Sabouroud Dextrose Agar (SDA) medium. Conventional methods, including polymerase chain reaction (PCR) and sequencing, were carried out for identification of fungal species. Indeed, antifungal susceptibility testing of yeast isolates was conducted according to Clinical Laboratory Standards Institute (CLSI M27-S3 and S4) protocol. The data was analysed using SPSS software version 20.

**Results:** Of 40 IPF patients, 22 (55%) were female and 18 (45%) were male. Seven (17.5%) of IPF patients were positive for fungal species as follows; four (10%) *Candida albicans* (*C. albicans*), two (5%) *Candida glabrata* (*C. glabrata*), and one (2.5%) *Aspergillus fumigatus* (*A. fumigatus*) were identified using the culture and PCR technique. A significant correlation was found between *C. albicans* colonization in upper respiratory system tract and presence of underlying disease in IPF patients ( $P < 0.05$ ). Antifungal susceptibility testing showed that all *C. albicans* isolates were resistant to itraconazole, whereas three (75%) *C. albicans* were resistant to amphotericin B. It was found that three (75%) and one (25%) *C. albicans* isolate were susceptible dose dependantly and resistant to fluconazole, respectively. Moreover, *C. glabrata* isolates were resistant to fluconazole, itraconazole, and amphotericin B.

**Conclusions:** Taken together, fungal species were detected in 17.5% of IPF patients. Resistance of *Candida* species to antifungal agents is growing, therefore isolation, identification, and antifungal susceptibility testing of fungal elements in IPF patients are necessary for appropriate treatment. However, determining an association between the fungal agents and devastating form of pulmonary fibrosis requires further investigation in the future.

**Keywords:** Idiopathic Pulmonary Fibrosis, Fungal Colonization, Antifungal Susceptibility Testing, Iran

## 1. Background

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease, and leads to tissue destruction, decline in lung function, respiratory distress, and finally decreased quality of life that causes death during three to

five years (1, 2). Although IPF is unknown, causes disease, and is poorly diagnosed, several factors, such as reduced lung alveolar epithelial cells, environmental factors, excessive sensitivity in the respiratory tract, high body mass index, and high grade on the modified Medical Research

Council (MRC) breathlessness scale contribute to pathogenesis of IPF. There is no definite care for IPF therapy and lung transplantation is the only alternative to save a small number of patients from the danger of death (3-6).

Because of changing viscosity of mucus in patients with progressive lung disease, use of broad-spectrum antibiotics and oral-respiratory steroid, the lung tissue is susceptible to colonization of fungal, bacterial, and viral agents, creating chronic infections (7). Previous studies investigated the role of microorganisms in the etiology of IPF pathogenesis (8, 9).

Colonization of *Candida* species in the respiratory system tract, especially in high risk patients with impaired lung epithelial cells, has been increased, which can improve pathogenicity of *Candida* and subsequently produce disease (10, 11).

It has been reported that *Candida albicans* (*C. albicans*) is the most common fungal agent isolated from the respiratory system of patients, whereas other *Candida* species are less frequent. The significance of *Candida* species is their ability to form a rigid network of yeast and hyphal complex as defined by biofilm structure with high resistance to common antifungal agents (12, 13). However, the role of fungi in progression of cystic fibrosis (CF) is well-known (10, 11, 14), while research on the prevalence of fungal colonization in IPF is limited. Therefore, the discovery of fungal colonization in IPF subjects is important for antifungal prophylaxis and treatment management of patients.

## 2. Objectives

This study aimed at investigating the identification of fungal agents in the respiratory system of IPF patients and determination of the anti-fungal susceptibility pattern of isolates, which is imperative for administrating a proper treatment in IPF cases.

## 3. Methods

### 3.1. Patients Characteristics and Specimens

Forty Iranian IPF patients were enrolled in this study, according to the results of lung NP swab or BAL or CT scans related to referral hospitals of Iran University of Medical Sciences (Tehran, Iran). During 12 months (from 2015 to 2016), 10 nasopharyngeal (NP) swabs and 30 bronchoalveolar lavage (BAL) specimens were collected from patients. The IPF cases had underlying disease, such as liver cirrhosis, pulmonary disease, and heart failure. Some cases took antibiotic and prednisolone for the treatment of IPF. Moreover, IPF cases did not show any clinical sign of fungal infections during the study. Demographic information of sub-

jects, including age, gender, familial history of lung disease, underlying disease, and use of drugs, were recorded. All patients filled out the consent form designed for the study. The study protocol was approved by the Research Ethics Committee of Iran University of Medical Sciences (IUMS) with ethical code number IR.IUMS.REC25488.

### 3.2. Culture of Samples

Specimens were collected in a sterile container and immediately transported to Medical Mycology Laboratory of Iran University. The samples were smeared on a slide and observed for the presence of fungal elements using 10% potassium hydroxide (KOH), directly under the light microscope. Then, an equal volume of 0.5% pancreatin was added and centrifuged. The precipitate was cultured on Sabouraud Dextrose Agar medium (SDA; Merck, Germany) with chloramphenicol, incubated for two weeks at 37°C and 25°C for yeast and filamentous fungi growth, respectively. Fungal growth was tested every two to three days. *Candida* species were identified by conventional methods, including Germ tube formation in Calf Fetal serum, Chlamyospore production on corn-meal agar (Difco, USA), color differentiation on CHROMagar *Candida* (Paris, France) and API 20C AUX (bioMérieux Italia S.p.A., Rome, Italy) (15). Finally, the isolates were identified using PCR and sequencing methods.

Indeed, filamentous fungi were recognized using morphological characterization on Czapek Dox Agar (Sigma-Aldrich, USA) and slide culture technique.

### 3.3. Genomic DNA Extraction from *Candida* Species

Fungal genomic DNA was extracted, as described previously. Briefly, genomic DNA was extracted using phenol, chloroform, isoamyl alcohol (25, 24, 1) glass beads, and lysis buffer (100 mM Tris pH 8, 100 mM NaCl, 1% SDS, Triton 2% X-100). The DNA was eluted in 20  $\mu$ L of Tris-EDTA buffer (5 mM), and stored at -20°C until for analysis. The quality and quantity of DNA was checked by gel electrophoresis and Nanodrop spectrophotometer (Thermo fisher scientific), respectively (16).

### 3.4. Polymerase Chain Reaction (PCR) and Sequencing Analysis

Polymerase chain reaction was accomplished to amplify universal primer ITS1-5.8S rDNA-ITS2 region sequence in ribosomal DNA. The sequences of ITS primers were ITS1 5'-TCC GTA GGT GAA CCT GCG G-3' and ITS4 5'-TCC GCT TAT TGA TAT GC-3', respectively.

The PCR assay was performed in a 25- $\mu$ L reaction mixture, including 12.5  $\mu$ L of Mastermix (Sinaclon, Iran), 2  $\mu$ L of forward and reverse primer (10 pmol), 1  $\mu$ L of DNA template

(25 ng), and sterile distilled water to reach a total volume of 25  $\mu$ L.

After initial denaturation of DNA at 95°C for five minutes, 30 cycles of amplification were completed in a thermal cycler (PeQlab, UK), including a denaturation step at 94°C for 30 seconds, an annealing step at 56°C for 30 seconds, an extension step at 72°C for one minute and a final extension step at 72°C for seven minutes. Proper positive and negative controls were used in each run. Then, the PCR products were electrophoresed through 1.8% agarose gel and visualized by ethidium bromide staining (17). The PCR products were sequenced by ITS primers from the Bioneer company (Korea).

All positive PCR amplicons were purified using a QI-Aquick PCR purification kit (Qiagen, UK) and were eluted in Tris-HCl (10 mM, pH 8.5) prior to sequencing, and then were sequenced in the forward direction, employing the ITS primer. The result of sequences was aligned, employing the MegAlign software (DNASTar Inc. Wisconsin, USA), and compared with those stored in the Genbank Data system using the BLAST alignment software tool (<http://www.blast.genome.ad.jp/>).

### 3.5. Antifungal Susceptibility Testing

Antifungal susceptibility was conducted with *Candida* isolates against fluconazole, amphotricin B, and itraconazole by microdilution broth, according to Clinical Laboratory Standards Institute CLSI (M27-S3) guidelines (18). Amphotericin B, itraconazole, and fluconazole (Sigma-Aldrich, USA) were prepared by the manufacturers standard assay powders. Microdilution trays (96 U-bottom shaped, Germany) containing antifungal dilutions were equipped and incubated at 35°C for 24 hours. In each experiment, proper positive and negative controls were used.

The MICs were determined by visual examination and considered as the lowest concentration of agents that inhibited the growth of yeast. The *C. glabrata* CBS 138 was used as the reference strain, and all experiments were conducted in duplicates. Species-specific clinical breakpoints (CBPs), recently published by the CLSI (M27-S4), were used for interpretation of results (19).

### 3.6. Statistical Analysis

The data were analyzed using the SPSS software, version 20 (SPSS, Chicago, IL, USA). The correlation between the presence of fungal species and patient characteristics were examined using either Pearson's chi-square or Fisher's exact test. Variations in the fungal agents colonization among underlying diseases were measured using the Mann Whitney U test. A P value of  $\leq 0.05$  was considered statistically significant.

## 4. Results

### 4.1. Study Population

Of 40 IPF cases, 22 (55%) were male and 18 (45%) were female. The male to female ratio was 22:18 patients (1.22). Patients' ages ranged between 18 and 70 years old (mean age: 60 years). The age of 21 (52.5%) patients was younger than 60, and 19 (45%) patients were older than 60 years old. Twenty-seven (68%) patients were undergoing treatment with antibiotic and prednisolone, whereas 13 (32%) patients only took prednisolone. The IPF patients, did not use any antifungal drugs during the sampling. All of the IPF patients had chronic pneumonia, had been diagnosed by CT scan in the recent years, and did not show any occupational exposure. Seven (17.5%) of 40 IPF patients represented fungal agent, however, no relationship was found between the presence of fungal species with age and gender of IPF patients. Demographic data of the IPF patients are shown in Table 1.

### 4.2. Characterization of Fungi Species by Conventional and PCR Methods

In direct microscopy examination of samples, seven (17.5%) of 40 specimens represented yeast, hypha, and branching of fungal hyphae forms. Indeed, these specimens were positive for fungal growth in SDA media. The distribution of fungi was as follows, *Candida albicans* four (10%), *Candida glabrata* two (5%), and (2.5%) *Aspergillus fumigatus* one (*A. fumigatus*).

*Candida* species were identified definitely by PCR and sequencing. By sequencing analysis, the *Candida* species showed high similarity in gene bank data and identified as *C. albicans* and *C. glabrata*. Also, *A. fumigatus* were identified mainly on morphological criteria.

### 4.3. Correlation Between Fungal Colonization and Risk Factors in IPF Patients

There was a significant association between the colonization of *C. albicans* in IPF patients and underlying diseases, including liver cirrhosis, pulmonary and heart disease as well as antibiotics and corticosteroid therapy ( $P < 0.05$ ). Interestingly, the findings showed no significant relationship between the *C. glabrata* colonization and risk factors in IPF patients ( $P = 0.08$ ). Patients with *A. fumigatus* colonization were older than those with *Candida* species. However, no significant relationship was found between the presence of *A. fumigatus* and other characteristics in IPF patients ( $P = 0.06$ ). The findings are summarized and presented in Table 1.

**Table 1.** The Correlation Between Demographic Data IPF Patients with Fungal Species

| Patients Data          | Total Number | <i>Candida albicans</i> |          | P Value           | <i>Candida glabrata</i> |          | P Value | <i>Aspergillus fumigatus</i> |          | P Value |
|------------------------|--------------|-------------------------|----------|-------------------|-------------------------|----------|---------|------------------------------|----------|---------|
|                        |              | Presence                | Absence  |                   | Presence                | Absence  |         | Presence                     | Absence  |         |
| <b>Age (mean = 60)</b> |              |                         |          | 0.65              |                         |          | 0.73    |                              |          | 0.52    |
| ≤ 60                   | 21 (53)      | 2 (9)                   | 19 (91)  |                   | 1 (5)                   | 20 (95)  |         | 1 (5)                        | 20 (95)  |         |
| > 60                   | 19 (47)      | 2 (10)                  | 17 (90)  |                   | 0 (0)                   | 19 (100) |         | 1 (5)                        | 18 (95)  |         |
| <b>Gender</b>          |              |                         |          | 0.41              |                         |          | 0.29    |                              |          | 0.45    |
| Female                 | 22 (55)      | 2 (9)                   | 20 (91)  |                   | 0 (0)                   | 22 (100) |         | 2 (9)                        | 20 (91)  |         |
| Male                   | 18 (45)      | 2 (11)                  | 16 (89)  |                   | 1 (6)                   | 17 (94)  |         | 0 (0)                        | 18 (100) |         |
| <b>Disease</b>         |              |                         |          | 0.04 <sup>a</sup> |                         |          | 0.18    |                              |          | 0.36    |
| IPF                    | 6 (15)       | 4 (67)                  | 2 (33)   |                   | 2 (33)                  | 4 (67)   |         | 1 (17)                       | 5 (83)   |         |
| IPF + other            | 34 (85)      | 0 (0)                   | 34 (100) |                   | 0 (0)                   | 34 (100) |         | 0 (0)                        | 34 (100) |         |
| <b>Type of drug +</b>  |              |                         |          | 0.39              |                         |          | 0.45    |                              |          | 0.32    |
| prednisolone           | 27 (68)      | 2 (7)                   | 25 (93)  |                   | 0 (0)                   | 27 (100) |         | 2 (7)                        | 25 (93)  |         |
| Prednisolone           | 13 (32)      | 2 (15)                  | 11 (85)  |                   | 1 (8)                   | 12 (92)  |         | 0 (0)                        | 13 (100) |         |
| <b>Severity</b>        |              |                         |          | 0.39              |                         |          | 0.58    |                              |          | 0.42    |
| 0                      | 4 (10)       | 0 (0)                   | 4 (100)  |                   | 0 (0)                   | 4 (100)  |         | 0 (0)                        | 4 (100)  |         |
| I                      | 17 (42)      | 1 (6)                   | 16 (94)  |                   | 1 (6)                   | 16 (94)  |         | 1 (6)                        | 16 (94)  |         |
| II                     | 19 (48)      | 3 (16)                  | 16 (84)  |                   | 0 (0)                   | 19 (100) |         | 0 (0)                        | 19 (100) |         |

<sup>a</sup> P value is statistically significant.

#### 4.4. Antifungal Susceptibility Testing

Regarding antifungal susceptibility findings, four (100%) isolates of *C. albicans* were resistant to itraconazole (MIC ≥ 1 µg/mL) and it was found that three (75%) isolates of *C. albicans* were resistant to amphotericin B (MIC ≥ 1 µg/mL), whereas three (75%) and one (25%) *C. albicans* isolates acted in a dose dependent manner (MIC ≥ 4 µg/mL) and were resistant to fluconazole (MIC ≥ 8 µg/mL), respectively. Also, 25% of isolates of *C. albicans* were sensitive (MIC = 0.5 µg/mL) to amphotericin B, while 75% of isolates were resistant to amphotericin B. Furthermore, *C. glabrata* isolates were resistant to fluconazole (MIC ≥ 64 µg/mL), itraconazole (MIC ≥ 1 µg/mL), and amphotericin B (MIC ≥ 1 µg/mL). The results are shown in Table 2. Breakpoint for fluconazole provided by CLSI M27-S4. As breakpoint for AMB and itraconazole was not provided by CLSI M27-S4, therefore, the researchers interpreted according to the M27-S3 document (18).

### 5. Discussion

The role of fungi in terms of colonization and pathogenesis of IPF are less well described. Notably, previous published data demonstrated the role of bacteria and viral infection in the pathogenesis of IPF (8, 9, 20-25), however, the role of fungal agents as etiology of IPF is less addressed. This reflects the fact that little attention has been

paid to the outcomes of fungal agents in IPF patients. For this reason, in the current study, the researchers evaluated the colonization of fungal agents in Iranian patients with IPF for the first time. Also, antifungal susceptibility of isolates was examined. Assessment of fungal agents in IPF patients needs greater attention because of colonization of fungal agents in IPF subjects with underlying disease, which may ultimately lead to lethal infection by dispersing to the blood stream.

To the best of the author's knowledge, this study was the first report of fungal colonization in Iranian IPF patients. The findings expressed that *C. albicans* was the most prevalent species isolated from IPF patients followed by *C. glabrata* and *A. fumigatus*.

Moreover, a significant correlation was found between the presence of *C. albicans* and predisposing factors in IPF patients that result in growth of *Candida* species colonization in the respiratory system, which leads to severe infections and morbidity in high risk patients.

The findings are consistent with other related studies that have focused on the pathogenesis of respiratory disease; peltrochelacsahuanga isolated *C. albicans* and *C. dubliniensis* with a similar percentage of the respiratory tract in cystic fibrosis (CF) patients (26, 27).

In a similar study performed by Gungor et al. in 2013, *Candida albicans* was the most common agent iso-

**Table 2.** Drug Susceptibility of *Candida* spp. Isolated from IPF Patients

| Clinical Isolates          | Fluconazole (MIC, µg/mL) |     |   | Itraconazole (MIC, µg/mL) |     |   | Amphotricin B (MIC, µg/mL) |     |   |
|----------------------------|--------------------------|-----|---|---------------------------|-----|---|----------------------------|-----|---|
|                            | S                        | SDD | R | S                         | SDD | R | S                          | SDD | R |
| <i>C. glabrata</i> (n = 2) | 0                        | 0   | 2 | 0                         | 0   | 2 | 0                          | 0   | 2 |
| <i>C. albicans</i> (n = 4) | 0                        | 3   | 1 | 0                         | 0   | 4 | 1                          | 0   | 3 |

Abbreviations: MIC, minimum inhibitory concentration; S, sensitive; SDD, susceptible-dose dependent; R, resistance.

lated from the respiratory tract of Turkish CF patients, although *C. parapsilosis*, *C. dubliniensis*, and *Aspergillus fumigatus* were reported in the second most common fungi. Similarity, the current findings reported that there is no correlation between *Candida* growth and age and gender of patients (10).

Gammelsrouud et al. reported that Children with CF had the highest prevalence of *Candida albicans* (11). Similarity, *Candida albicans* was the predominant yeast isolated from Turkish patients with CF, followed by *C. parapsilosis* and *C. dubliniensis*. Also, *Aspergillus fumigatus* detected the most common filamentous fungus (11).

Horre et al. in 2004 investigated *Wangiella dermatitidis* as the black yeast could be colonized and recovered from sputum culture of CF patients (14).

Indeed, in a previous study carried out by Pihet, *Aspergillus fumigatus*, *Scedosporium apiospermum*, *Aspergillus terreus*, and *Candida albicans* offered the main fungal species in respiratory secretions associated with CF cases, nevertheless, other species are less common (28).

Interestingly, in a case report by Kumar, coexistence of aspergilloma (fungal ball) with Idiopathic pulmonary fibrosis (IPF) was reported in 55-year-old female (29).

Antifungal susceptibility test indicated a high rate of resistance in *Candida albicans* and *C. glabrata* isolates. Overall, 100% of the isolates were resistant to itraconazole, 75% of isolates were resistant to amphotricin B, and 25% were resistant to fluconazole. *Candida glabrata* isolates were resistant to fluconazole, itraconazole, and amphotricin B. It is well known that the resistance of *Candida glabrata* is developing in clinical isolates, and previous studies supported this data. This resistance may be related to genetic diversity of species and the emergence of resistant genes due to using common antifungal drugs (12, 13, 30).

The main obstacle of non-*albicans Candida* infection is high intrinsic resistance to several antifungal drugs, especially azoles. Additionally, the progress of antifungal resistance, during prolonged and prophylactic treatment, leads to a decrease in therapeutic efficacies (31).

Therefore, management and appropriate antifungal therapy must be mentioned for fungal infection treatment of IPF patients and to decrease the drug resistance rate. Some of the limitations of the current study was the low

sample size of IPF patients due to the low rate of IPF incidence, nevertheless, a more dependable finding will be accomplished in a large population.

### 5.1. Conclusions

In conclusion, in IPF patients, fungi may contribute to destruction of lung function and infection. However, the clinical relevance of the fungal airway colonization and its correlation with IPF still needs consideration. Based on the current findings, yeast and filamentous fungi may be responsible for local inflammatory response and leads to infection in susceptible patients.

In addition, the effects of antifungal prophylaxis and cancer therapy medications can be investigated on *Candida* colonization rate.

### Acknowledgments

The authors have thank the Iran University of Medical Sciences (IUMS) for their financial support.

### Footnotes

**Authors' Contribution:** All authors cooperated in this study.

**Conflict of Interests:** The authors declare no conflict of interest.

**Ethical Approval:** The study protocol was approved by the Research Ethics Committee of Iran University of Medical Sciences (IUMS) with ethical code number (IR.IUMS.REC25488).

**Funding/Support:** This study was supported by the research deputy of Iran University of Medical Sciences (IUMS) (grant number 25488).

**Patient Consent:** All patients filled out the consent form.

### References

- King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. *Lancet*. 2011;378(9807):1949-61. doi: 10.1016/S0140-6736(11)60052-4. [PubMed: 21719092].

2. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. *Am J Respir Crit Care Med*. 2011;**183**(6):788–824. doi: [10.1164/rccm.2009-040GL](https://doi.org/10.1164/rccm.2009-040GL). [PubMed: [21471066](https://pubmed.ncbi.nlm.nih.gov/21471066/)]. [PubMed Central: [PMC5450933](https://pubmed.ncbi.nlm.nih.gov/PMC5450933/)].
3. Daniels CE, Ryu JH. Treatment of idiopathic pulmonary fibrosis. *Semin Respir Crit Care Med*. 2006;**27**(6):668–76. doi: [10.1055/s-2006-957338](https://doi.org/10.1055/s-2006-957338). [PubMed: [17195143](https://pubmed.ncbi.nlm.nih.gov/17195143/)].
4. Salisbury ML, Xia M, Zhou Y, Murray S, Tayob N, Brown KK, et al. Idiopathic pulmonary fibrosis: Gender-age-physiology index stage for predicting future lung function decline. *Chest*. 2016;**149**(2):491–8. doi: [10.1378/chest.15-0530](https://doi.org/10.1378/chest.15-0530). [PubMed: [26425858](https://pubmed.ncbi.nlm.nih.gov/26425858/)]. [PubMed Central: [PMC4944785](https://pubmed.ncbi.nlm.nih.gov/PMC4944785/)].
5. Javadi A, Adibi P, Ataei B, Nokhodian Z, Yaran M. Surveillance of acute respiratory infections among outpatients: A pilot study in Isfahan city. *J Res Med Sci*. 2015;**20**(2):115–21. [PubMed: [25983761](https://pubmed.ncbi.nlm.nih.gov/25983761/)]. [PubMed Central: [PMC4400703](https://pubmed.ncbi.nlm.nih.gov/PMC4400703/)].
6. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. *N Engl J Med*. 2014;**370**(22):2071–82. doi: [10.1056/NEJMoa1402584](https://doi.org/10.1056/NEJMoa1402584). [PubMed: [24836310](https://pubmed.ncbi.nlm.nih.gov/24836310/)].
7. Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. *Clin Microbiol Rev*. 2002;**15**(2):194–222. doi: [10.1128/CMR.15.2.194-222.2002](https://doi.org/10.1128/CMR.15.2.194-222.2002). [PubMed: [11932230](https://pubmed.ncbi.nlm.nih.gov/11932230/)]. [PubMed Central: [PMC118069](https://pubmed.ncbi.nlm.nih.gov/PMC118069/)].
8. Molyneux PL, Maher TM. The role of infection in the pathogenesis of idiopathic pulmonary fibrosis. *Eur Respir Rev*. 2013;**22**(129):376–81. doi: [10.1183/09059180.00000713](https://doi.org/10.1183/09059180.00000713). [PubMed: [23997064](https://pubmed.ncbi.nlm.nih.gov/23997064/)].
9. Molyneux PL, Cox MJ, Willis-Owen SA, Mallia P, Russell KE, Russell AM, et al. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med*. 2014;**190**(8):906–13. doi: [10.1164/rccm.201403-0541OC](https://doi.org/10.1164/rccm.201403-0541OC). [PubMed: [25184687](https://pubmed.ncbi.nlm.nih.gov/25184687/)]. [PubMed Central: [PMC4299577](https://pubmed.ncbi.nlm.nih.gov/PMC4299577/)].
10. Gungor O, Tamay Z, Guler N, Erturan Z. Frequency of fungi in respiratory samples from Turkish cystic fibrosis patients. *Mycoses*. 2013;**56**(2):123–9. doi: [10.1111/j.1439-0507.2012.02221.x](https://doi.org/10.1111/j.1439-0507.2012.02221.x). [PubMed: [22747891](https://pubmed.ncbi.nlm.nih.gov/22747891/)].
11. Gammelsrud KW, Sandven P, Hoiby EA, Sandvik L, Brandtzaeg P, Gaustad P. Colonization by *Candida* in children with cancer, children with cystic fibrosis, and healthy controls. *Clin Microbiol Infect*. 2011;**17**(12):1875–81. doi: [10.1111/j.1469-0691.2011.03528.x](https://doi.org/10.1111/j.1469-0691.2011.03528.x). [PubMed: [21745258](https://pubmed.ncbi.nlm.nih.gov/21745258/)].
12. Santos A, Galdino ACM, Mello TP, Ramos LS, Branquinha MH, Bolognese AM, et al. What are the advantages of living in a community? A microbial biofilm perspective!. *Mem Inst Oswaldo Cruz*. 2018;**113**(9). e180212. doi: [10.1590/0074-02760180212](https://doi.org/10.1590/0074-02760180212). [PubMed: [30066753](https://pubmed.ncbi.nlm.nih.gov/30066753/)]. [PubMed Central: [PMC6057313](https://pubmed.ncbi.nlm.nih.gov/PMC6057313/)].
13. Desai JV, Mitchell AP, Andes DR. Fungal biofilms, drug resistance, and recurrent infection. *Cold Spring Harb Perspect Med*. 2014;**4**(10). doi: [10.1101/cshperspect.a019729](https://doi.org/10.1101/cshperspect.a019729). [PubMed: [25274758](https://pubmed.ncbi.nlm.nih.gov/25274758/)]. [PubMed Central: [PMC4200207](https://pubmed.ncbi.nlm.nih.gov/PMC4200207/)].
14. Horre R, Schaal KP, Siekmeier R, Sterzik B, de Hoog GS, Schnitzler N. Isolation of fungi, especially *Exophiala dermatitidis*, in patients suffering from cystic fibrosis. A prospective study. *Respiration*. 2004;**71**(4):360–6. doi: [10.1159/000079640](https://doi.org/10.1159/000079640). [PubMed: [15316209](https://pubmed.ncbi.nlm.nih.gov/15316209/)].
15. Liguori G, Di Onofrio V, Lucariello A, Galle F, Signoriello G, Colella G, et al. Oral candidiasis: A comparison between conventional methods and multiplex polymerase chain reaction for species identification. *Oral Microbiol Immunol*. 2009;**24**(1):76–8. doi: [10.1111/j.1399-302X.2008.00447.x](https://doi.org/10.1111/j.1399-302X.2008.00447.x). [PubMed: [19121074](https://pubmed.ncbi.nlm.nih.gov/19121074/)].
16. Roudbarmohammadi S, Roudbary M, Bakhshi B, Katirae F, Mohammadi R, Falahati M. ALS1 and ALS3 gene expression and biofilm formation in *Candida albicans* isolated from vulvovaginal candidiasis. *Adv Biomed Res*. 2016;**5**:105. doi: [10.4103/2277-9175.183666](https://doi.org/10.4103/2277-9175.183666). [PubMed: [27376044](https://pubmed.ncbi.nlm.nih.gov/27376044/)]. [PubMed Central: [PMC4918214](https://pubmed.ncbi.nlm.nih.gov/PMC4918214/)].
17. Esteve-Zarzoso B, Belloch C, Uruburu F, Querol A. Identification of yeasts by RFLP analysis of the 5.8S rRNA gene and the two ribosomal internal transcribed spacers. *Int J Syst Bacteriol*. 1999;**49 Pt 1**:329–37. doi: [10.1099/00207713-49-1-329](https://doi.org/10.1099/00207713-49-1-329). [PubMed: [10028278](https://pubmed.ncbi.nlm.nih.gov/10028278/)].
18. Wayne P. *Clinical and Laboratory Standards Institute: Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard; CLSI document M27-A3*. CLSI 2008a. **28**. 2008.
19. Santos ER, Dal Forno CF, Hernandez MG, Kubica TF, Venturini TP, Chassot F, et al. Susceptibility of *Candida* spp. isolated from blood cultures as evaluated using the M27-A3 and new M27-S4 approved breakpoints. *Rev Inst Med Trop Sao Paulo*. 2014;**56**(6):477–82. doi: [10.1590/S0036-46652014000600004](https://doi.org/10.1590/S0036-46652014000600004). [PubMed: [25351540](https://pubmed.ncbi.nlm.nih.gov/25351540/)]. [PubMed Central: [PMC4296866](https://pubmed.ncbi.nlm.nih.gov/PMC4296866/)].
20. Windisch W, Schildgen V, Malecki M, Lenz J, Brockmann M, Karagiannidis C, et al. Detection of HBov DNA in idiopathic lung fibrosis, Cologne, Germany. *J Clin Virol*. 2013;**58**(1):325–7. doi: [10.1016/j.jcv.2013.05.020](https://doi.org/10.1016/j.jcv.2013.05.020). [PubMed: [23806665](https://pubmed.ncbi.nlm.nih.gov/23806665/)].
21. Ringshausen FC, Tan AY, Allander T, Borg I, Arinir U, Kronsbein J, et al. Frequency and clinical relevance of human bocavirus infection in acute exacerbations of chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis*. 2009;**4**:111–7. doi: [10.2147/COPD.S4801](https://doi.org/10.2147/COPD.S4801). [PubMed: [19436697](https://pubmed.ncbi.nlm.nih.gov/19436697/)]. [PubMed Central: [PMC2672801](https://pubmed.ncbi.nlm.nih.gov/PMC2672801/)].
22. Wurzel DF, Marchant JM, Clark JE, Mackay IM, Wang CY, Sloots TP, et al. Respiratory virus detection in nasopharyngeal aspirate versus bronchoalveolar lavage is dependent on virus type in children with chronic respiratory symptoms. *J Clin Virol*. 2013;**58**(4):683–8. doi: [10.1016/j.jcv.2013.09.016](https://doi.org/10.1016/j.jcv.2013.09.016). [PubMed: [24125830](https://pubmed.ncbi.nlm.nih.gov/24125830/)].
23. Ushiki A, Yamazaki Y, Hama M, Yasuo M, Hanaoka M, Kubo K. Viral infections in patients with an acute exacerbation of idiopathic interstitial pneumonia. *Respir Investig*. 2014;**52**(1):65–70. doi: [10.1016/j.resinv.2013.07.005](https://doi.org/10.1016/j.resinv.2013.07.005). [PubMed: [24388373](https://pubmed.ncbi.nlm.nih.gov/24388373/)].
24. Moore BB, Moore TA. Viruses in idiopathic pulmonary fibrosis. Etiology and exacerbation. *Ann Am Thorac Soc*. 2015;**12 Suppl 2**:S186–92. doi: [10.1513/AnnalsATS.201502-088AW](https://doi.org/10.1513/AnnalsATS.201502-088AW). [PubMed: [26595738](https://pubmed.ncbi.nlm.nih.gov/26595738/)]. [PubMed Central: [PMC4722834](https://pubmed.ncbi.nlm.nih.gov/PMC4722834/)].
25. Moradi P, Keyvani H, Javad Mousavi SA, Karbalaie Niya MH, Esghaei M, Bokharaei-Salim F, et al. Investigation of viral infection in idiopathic pulmonary fibrosis among Iranian patients in Tehran. *Microb Pathog*. 2017;**104**:171–4. doi: [10.1016/j.micpath.2017.01.030](https://doi.org/10.1016/j.micpath.2017.01.030). [PubMed: [28115263](https://pubmed.ncbi.nlm.nih.gov/28115263/)].
26. Peltroche-Llacsahuanga H, Dohmen H, Haase G. Recovery of *Candida dubliniensis* from sputum of cystic fibrosis patients. *Mycoses*. 2002;**45**(1-2):15–8. doi: [10.1046/j.0933-7407.2001.00719.x](https://doi.org/10.1046/j.0933-7407.2001.00719.x). [PubMed: [11856431](https://pubmed.ncbi.nlm.nih.gov/11856431/)].
27. Loreto ES, Scheid LA, Nogueira CW, Zeni G, Santurio JM, Alves SH. *Candida dubliniensis*: Epidemiology and phenotypic methods for identification. *Mycopathologia*. 2010;**169**(6):431–43. doi: [10.1007/s11046-010-9286-5](https://doi.org/10.1007/s11046-010-9286-5). [PubMed: [20490751](https://pubmed.ncbi.nlm.nih.gov/20490751/)].
28. Pihet M, Carrere J, Cimon B, Chabasse D, Delhaes L, Symoens F, et al. Occurrence and relevance of filamentous fungi in respiratory secretions of patients with cystic fibrosis—a review. *Med Mycol*. 2009;**47**(4):387–97. doi: [10.1080/13693780802609604](https://doi.org/10.1080/13693780802609604). [PubMed: [19107638](https://pubmed.ncbi.nlm.nih.gov/19107638/)].
29. Kumar N, Mishra M, Singhal A, Kaur J, Tripathi V. Aspergilloma coexisting with idiopathic pulmonary fibrosis: A rare occurrence. *J Postgrad Med*. 2013;**59**(2):145–8. doi: [10.4103/0022-3859.113841](https://doi.org/10.4103/0022-3859.113841). [PubMed: [23793319](https://pubmed.ncbi.nlm.nih.gov/23793319/)].
30. Henry KW, Nickels JT, Edlind TD. Upregulation of ERG genes in *Candida* species by azoles and other sterol biosynthesis inhibitors. *Antimicrob Agents Chemother*. 2000;**44**(10):2693–700. doi: [10.1128/AAC.44.10.2693-2700.2000](https://doi.org/10.1128/AAC.44.10.2693-2700.2000). [PubMed: [10991846](https://pubmed.ncbi.nlm.nih.gov/10991846/)]. [PubMed Central: [PMC90137](https://pubmed.ncbi.nlm.nih.gov/PMC90137/)].
31. Tscherner M, Schwarzmüller T, Kuchler K. Pathogenesis and antifungal drug resistance of the human fungal pathogen *Candida glabrata*. *Pharmaceuticals*. 2011;**4**(1):169–86. doi: [10.3390/ph4010169](https://doi.org/10.3390/ph4010169).